Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Nesolicaftor (PTI-428) in Cystic Fibrosis
NCT02718495Phase 2Completed
- Sponsor
- Proteostasis Therapeutics
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of nesolicaftor in cystic fibrosis (CF), sponsored by Proteostasis Therapeutics. Started Jul 2016; status: completed.
02
Drugs
nesolicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02718495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718495.